

2017

The t6A Modification Acts as a Positive Determinant for the Anticodon Nuclease Prrc, and is Distinctively Nonessential in *Streptococcus mutans*

Jo Marie Bacusmo
University of Florida

Silvia S. Orsini
University of Florida

Jennifer Hu
Massachusetts Institute of Technology


Michael DeMott
Massachusetts Institute of Technology

Patrick C. Thiaville
University of Florida

See next page for additional authors

Let us know how access to this document benefits you.

Follow this and additional works at: https://pdxscholar.library.pdx.edu/chem_fac

 Part of the [Chemistry Commons](#), and the [Molecular Biology Commons](#)

Citation Details

Bacusmo, J. M., Orsini, S. S., Hu, J., DeMott, M., Thiaville, P. C., Elfarash, A., ... & Iwata-Reuyl, D. (2017). The t6A modification acts as a positive determinant for the anticodon nuclease PrrC, and is distinctively nonessential in *Streptococcus mutans*. *RNA biology*, 1-10.

This Post-Print is brought to you for free and open access. It has been accepted for inclusion in Chemistry Faculty Publications and Presentations by an authorized administrator of PDXScholar. For more information, please contact pdxscholar@pdx.edu.

Authors

Jo Marie Bacusmo, Silvia S. Orsini, Jennifer Hu, Michael DeMott, Patrick C. Thiaville, Ameer Elfarash, Mellie June Paulines, Diego Rojas-Benítez, Birthe Meineke, Christopher Deutsch, Dirk Iwata-Reuyl, Patrick A. Limbach, Peter C. Dedon, Kelly C. Rice, Stewart Shuman, and Valérie de Crécy-Lagard

t⁶A a toxin determinant

Review

The t⁶A modification acts as a positive determinant for the anticodon nuclease PrrC, and is distinctively nonessential in *Streptococcus mutans*

Jo Marie Bacusmo¹, Silvia S. Orsini¹, Jennifer Hu², Michael DeMott², Patrick C. Thiaville^{1,3,4,*}, Ameer Elfarash^{1,5}, Mellie June Paulines⁶, Diego Rojas-Benítez⁷, Birthe Meineke⁸, Chris Deutsch⁹, Dirk Iwata-Reuyl⁹, Patrick A. Limbach⁶, Peter C. Dedon², Kelly C. Rice¹, Stewart Shuman⁸, and Valérie de Crécy-Lagard^{1,4,*}

¹Department of Microbiology and Cell Science, IFAS, University of Florida, Gainesville, FL 32611, USA

²Center for Environmental Health Sciences, Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA

³Genetics and Genomics Graduate Program, University of Florida, Gainesville, FL 32610, USA

⁴University of Florida Genetics Institute, University of Florida, Gainesville, FL 32610, USA

⁵Genetic Department, Faculty of Agriculture, Assiut University, 71516 Assuit, Egypt

⁶Rieveschl Laboratories for Mass Spectrometry, Department of Chemistry, University of Cincinnati, Cincinnati OH 45221, USA

⁷Centro de Regulación del Genoma. Facultad de Ciencias – Universidad de Chile, Santiago, Chile

⁸Molecular Biology Program, Sloan-Kettering Institute, 1275 York Avenue, New York, NY 10065, USA

⁹Department of Chemistry, Portland State University, Portland, OR 97207, USA

*Current Address: NeXtGen Biologics Inc., Gainesville, FL 32601, USA

Corresponding author E-mail: vcrecy@ufl.edu (VdC-L), Microbiology and Cell Science, IFAS, University of Florida, PO Box 110700, Gainesville, FL, United States, 32611

Abstract

Endoribonuclease toxins (ribotoxins) are produced by bacteria and fungi to respond to stress, eliminate non-self competitor species, or interdict virus infection. PrrC is a bacterial ribotoxin that targets and cleaves tRNA^{Lys}_{UUU} in the anticodon loop. *In vitro* studies suggested that the post-transcriptional modification threonylcarbamoyl adenosine (t⁶A) is required for PrrC activity but this prediction had never been validated *in vivo*. Here, by using t⁶A-deficient yeast derivatives, it is shown that t⁶A is a positive determinant for PrrC proteins from various bacterial species. *Streptococcus mutans* is one of the few bacteria where the t⁶A synthesis gene *tsaE* (*brpB*) is dispensable and its genome encodes a PrrC toxin. We had previously shown using an HPLC-based assay that the *S. mutans tsaE* mutant was devoid of t⁶A. However, we describe here a novel and a more sensitive hybridization-based t⁶A detection method (compared to HPLC) that showed t⁶A was still present in the *S. mutans ΔtsaE*, albeit at greatly reduced levels (93% reduced compared to WT). Moreover, mutants in two other *S. mutans* t⁶A synthesis genes (*tsaB* and *tsaC*) were shown to be totally devoid of the modification thus confirming its dispensability in this organism. Furthermore, analysis of t⁶A modification ratios and of t⁶A synthesis genes mRNAs levels in *S. mutans* suggest they may be regulated by growth phase.

Keywords

RNA maturation, translation, modified nucleosides, t⁶A detection

Abbreviations

t⁶A or t⁶A₃₇ threonylcarbamoyladenine

ASL Anticodon Stem Loop

TCTC ThreonylCarbamoyl Transferase Complex

Introduction

tRNA molecules are heavily modified post-transcriptionally to ensure translational accuracy and cell survival¹. tRNA Anticodon Stem Loops (ASLs) (Figure 1) make excellent targets for ribotoxins (or anticodon nucleases, ACNases) in toxin/antitoxin (TA) modules that can be utilized by organisms to eliminate competition or for suicidal functions under stress or phage attack^{2,3}. Different ACNases have been characterized with very specific tRNA cleavage patterns. The *Escherichia coli* toxins Colicin E5 and Colicin D target tRNAs with a QUN anticodon (Q being the modified base Queuosine)⁴ and tRNA^{Arg} isoacceptors, respectively⁵. The *Mycobacterium tuberculosis* toxin VapC-mt4 targets tRNA^{Ala}_{UGC}, tRNA^{Ser}_{GCU} and tRNA^{Ser}_{GGA}⁶, while the enteric VapC proteins target tRNA^{iniMet}_{CAU}⁷. MazF-mt9, from the same organism, targets the ASL of tRNA^{Lys}_{UUU}⁸. Whereas none of these toxins require the presence of tRNA modifications for cleavage, there are other ACNases for which activity is dependent on such modifications. For example, the PaT toxin from *Pichia acacia* targets the methyl group of 5-methoxycarbonylmethyl-2-thiouridine (mcm⁵s²U₃₄) containing tRNA^{Gln}_{UUG}, as evidenced by the resistance of the mcm⁵s²U₃₄ deficient *Saccharomyces cerevisiae trm9Δ* strain⁹. Another example is the γ-toxin from *Kluyveromyces lactis*, which recognizes the wobble modification mcm⁵U of tRNA^{Glu}_{UUC}¹⁰.

One of the first identified ACNases was *E. coli* PrrC (PrrC_{Ec})¹¹. Infection of *E. coli* by bacteriophage T4 activates PrrC, which then cleaves the ASL of tRNA^{Lys}_{UUU} to disrupt translation of late T4 proteins (primarily structural and assembly viral proteins)¹² and contain the infection in a suicidal gesture^{2,13}. PrrC has been shown to cleave native tRNA^{Lys}_{UUU} *in vitro* but not the corresponding unmodified transcript¹⁴⁻¹⁶, leading to the hypothesis that a post-

transcriptional modification on tRNA^{Lys} was a requirement for PrrC activity. Two complex post-transcriptional modifications are found in the ASL of tRNA^{Lys} in both *E. coli* and *S. cerevisiae*¹⁷. First, the U at position 34 is modified to 5-methylaminomethyl-2-thiouridine (mnm⁵S²U) in *E. coli* and to 5-methoxycarbonylmethyluridine (mcm⁵U) in *S. cerevisiae*. Second, the A at position 37 is modified to threonylcarbamoyl adenosine (t⁶A) in both organisms (Figure 1). In some organisms, t⁶A is further modified into complex derivatives such as cyclic-t⁶A (ct⁶A), N⁶-methyl-t⁶A (m⁶t⁶A)^{6,7} and 2-methylthio-t⁶A (ms²t⁶A)¹⁸. Unlike the γ -toxin from *K. lactis*, PrrC was still toxic when expressed in *S. cerevisiae* *elp3* Δ and *trm9* Δ derivatives (lacking mcm⁵U₃₄)¹⁶. This left the t⁶A modification of tRNA^{Lys} as a logical candidate for the missing positive determinant for cleavage by PrrC.

t⁶A is one of the few universal modifications on the ASL found in most tRNAs that decode ANN codons¹⁷. The t⁶A synthesis pathway has recently been elucidated in all domains of life (see¹⁹ for review). In bacteria, the first enzyme L-threonylcarbamoyladenylate synthase (EC 2.7.7.87), which can be of type 1 (TsaC) or type 2 (TsaC2), produces L-threonylcarbamoyladenylate (TC-AMP). In yeast, the equivalent protein is encoded by the *TCS2* (*SUA5*) gene. The TC-AMP intermediate is then used by the bacterial tRNA adenosine (37) threonylcarbamoyltransferase complex, which is composed of the three subunits TsaD, TsaB and TsaE to transfer the threonylcarbamoyl moiety to the target adenosine-37 of the target tRNA. In the yeast cytoplasm, the transferase complex is composed of the KEOPS complex subunits (encoded by the *TCS3/KAE1*, *TCS5/BUD32*, *TCS6/PCC1*, *TCS7/CGI121*, *TCS8/GON7* genes) whereas *TCS4* (*QRI7*) fulfills that role in yeast mitochondria. The *tsaBCDE* genes are generally essential in bacteria²⁰, and in *E. coli*, it was shown that t⁶A is a strict determinant for the bacterial-type isoleucyl-tRNA synthetase (IleRS) and possibly for lysidine synthase (Tils), roles that easily explain the essentiality phenotype. However, the t⁶A synthesis genes can be deleted in some bacteria, including *Streptococcus mutans*, an oral pathogen that thrives in multi-species biofilms on tooth surfaces²⁰. In this organism, the Δ *tsaE* (*brpE*/SMU.409) strain is viable although growth rate was affected. The mutant is also compromised in biofilm formation, and is more sensitive than the wild-type to low pH and oxidative stress²¹. The *tsaE/brpE* gene is co-transcribed in *S. mutans* UA159 with *brpA*, which encodes a surface-associated protein with global effects on *S. mutans* biofilm formation and tolerance to antibiotic, acid, and oxidative stresses^{22,23}. In a systematic study of a gene deletion library of *S. mutans*, *tsaC* (SMU.1083c) was found to be dispensable and its

deletion also led to poor acid survival and biofilm formation deficiencies²⁴. Using an HPLC based assay, we previously showed that the *S. mutans* Δ *tsaE* strain lacked t⁶A²⁰, but the t⁶A levels in the *S. mutans* *tsaC* mutant have not been analyzed. More generally, the molecular rationale underlying the pH sensitivity and biofilm defects of t⁶A deficient *S. mutans* strains is unknown.

Toxin/antitoxin modules such as MazE/F or RelB/E have been suggested to play a role in the survival of *S. mutans* in its harsh environment, possibly by triggering dormancy states^{25,26}. A *prcC* homolog is also found in *S. mutans* (SMU.893/PrrC_{Sm}) just upstream of the *relBE* toxin/antitoxin genes²⁵. The corresponding PrrC_{Sm} protein is comparably active as a cytotoxin in yeast as its *E. coli* counterpart²⁷. However, the role of PrrC in *S. mutans* physiology is not clear. The *prcC* gene is co-transcribed in an operon with the genes *hdsMSR* that encode the subunits of the type Ic DNA Restriction-Modification (R-M) complex *prl*²⁸. PrrC_{Ec} is kept in an inactive state by binding to an *Ecoprl*/DNA complex, but the toxin can be activated by several mechanisms²⁸. One such example is during infection by T4 phage, which results in the binding of *Ecoprl* by T4-encoded polypeptide STP, thus releasing active PrrC_{Ec}. Other stresses that affect the activity of type I DNA restriction endonucleases also appear to activate PrrC_{Ec} and possibly disable protein synthesis²⁸. Although, it is known that increased levels of dTTP combined with GTP hydrolysis activates the PrrC_{Ec} ACNase, the triggers in other organisms such as *S. mutans* remain a mystery. Furthermore, it is unclear whether the PrrC toxin plays a role in dormancy or programmed cell death (PCD), states known to be important for *S. mutans* survival²⁹.

In this work, we show that t⁶A is a positive determinant for both the *E. coli* and *S. mutans* PrrC toxins. Using a newly developed and more sensitive than HPLC t⁶A detection method (based on the previously described “positive hybridization in the absence of i⁶A37” (*PHA6*) assay³⁰⁻³²), we demonstrate that t⁶A is not absent in the *S. mutans* Δ *tsaE* strain as previously thought, but is present at greatly reduced levels compared to wild type. The Δ *tsaC* and Δ *tsaB* mutants, however, were also viable but appeared to completely lack this modification but are still viable. We also showed that in *S. mutans*, expression of both the *tsaBCE* genes and t⁶A levels are both growth-phase dependent, being greatly reduced in stationary phase.

Results

The modification t⁶A is a positive determinant for cleavage of tRNA by PrrC

If t⁶A is a determinant for PrrC, then t⁶A⁻ yeast strains should be resistant to the PrrC-induced growth inhibition previously observed in WT cells¹⁶. To test this hypothesis, a plasmid containing the *E. coli prrC* gene under the control of galactose inducible promoter (pYCPrrC_{Ec})¹⁶ was transformed into wild-type (WT) and t⁶A deficient yeast strains. As shown Figure 2A, the BY4741 (pYCPrrC_{Ec}) cells did not grow in the presence of galactose whereas the t⁶A deficient *tcs3Δ* (pYCPrrC_{Ec}) strain grew. The *tcs4Δ* strain (containing a deletion for the mitochondrial-specific t⁶A synthesis gene but with a fully functional cytosolic t⁶A biosynthesis machinery) was sensitive to the PrrC toxin similar to that observed in the WT strain. The strains carrying the control vector (pRS415) showed no difference in growth between induced and non-induced conditions.

A difficulty when working with most t⁶A deficient yeast strains is their poor growth on minimal media supplemented with carbon sources other than glucose³³. The *tcs8Δ* strain is an exception as it is devoid of t⁶A but its growth on minimal media is robust enough for reproducible growth tests³³. This strain was thus used to compare the toxicity of the PrrC_{Ec} and *S. mutans* PrrC (PrrC_{Sm}) toxins in yeast and the role of t⁶A in this toxicity. The empty vector pYCplac111 and a catalytically inactive variant of PrrC_{Ec} bearing a Lys to Ala mutation at position 46 (PrrC_{Ec} K46A)¹⁶ were used as negative controls. As shown in Figure 2B, *tcs8Δ* is resistant to the expression of PrrC toxins from both *E. coli* and *S. mutans* while BY4741 is not. As expected, overexpression of any of the control plasmids did not affect growth of the BY4741 or *tcs8Δ* strains. These results confirmed the prediction that t⁶A is a positive determinant for the PrrC toxins from both *E. coli* and *S. mutans*.

Development of a sensitive hybridization based t⁶A detection assay

To explore the role of t⁶A in *S. mutans* physiology, a more sensitive detection assay was required. Inspired by the assay developed for the detection of i⁶A by Northern blot (PHA6)³⁰, a Northern blot assay was developed for the detection of t⁶A³⁴. The premise of the assay is based on the carbamoylthreonyl group preventing hybridization of an ASL probe spanning position 37 (Figure 1). It is predicted that the extent of hybridization will increase as the levels of

t⁶A modification decrease. A probe spanning the TΨC loop of the tRNA can be used as an internal control for tRNA quantification. For this assay, purified bulk tRNAs were spotted and cross-linked onto neutral nylon membranes and detected with biotinylated probes (Table S1) to allow detection with streptavidin-labeled Horseradish Peroxidase (HRP).

tRNA extracted from yeast BY4741, *tcs2Δ*, *tcs4Δ*, and *tcs3Δ* strains, were spotted onto nylon membranes in duplicate. One membrane was treated with a biotinylated probe annealing to the TΨC loop and the second membrane was treated with the ASL probe for tRNA^{Ile}_{GAU}. As shown in Figure 3A, only tRNAs from t⁶A deficient strains *tcs2Δ* and *tcs3Δ* hybridized with the ASL probe, while no hybridization is observed with BY4741 and minimal hybridization with *tcs4Δ*. tRNAs from all strains hybridized with the TΨC probe showing relative quantities of tRNAs spotted on the membrane. These results are consistent with t⁶A detection via HPLC³³. The limit of detection of this method for yeast bulk tRNA was found to be 10 ng (Figure 3B).

This assay was then extended to tRNAs from the bacterial model *E. coli* and to different tRNA isoacceptors. t⁶A is essential in *E. coli* making it impossible to isolate tRNAs from a t⁶A deficient strain, therefore *in vitro* transcribed tRNA was used as negative control using probes specific for tRNA^{Ile}_{GAU} and tRNA^{Thr}_{GGU}. As shown Figure 3C, both wild type and *in vitro* transcribed tRNAs anneal to the TΨC probe, while only the transcripts anneal to the ASL probe. Similar results were obtained with probes specific for with *E. coli* tRNA^{Thr}_{GGU}. This new assay was named Positive Hybridization in the Absence of t⁶A, or PHAt6A Assay. This method allows one to detect t⁶A in specific tRNAs with a sensitivity that now allows the exploration of the role of t⁶A in bacterial physiology generally, and more specifically in *S. mutans*.

t⁶A is not essential in *S. mutans* but the *tsaE* mutant does contain residual amounts of the modification

Previous analysis of bulk tRNA extracted from the *S. mutans* Δ *tsaE* strain using HPLC indicated that no t⁶A was present in that background²⁰. However, when using the PHAt6A method with probes specific for *S. mutans* tRNA^{Ile}_{GAU}, faint annealing was observed, which made us consider that t⁶A may still be present (Figure 4A). To investigate this result further, each corresponding tRNA preparation was analyzed by mass spectrometry (MS), which demonstrated

that t⁶A was present in the *ΔtsaE* strain but in lower amounts (~7% t⁶A modified) than the wild-type (Figure 4B and Figure S1A). This result made us question our prior conclusions on the dispensability of t⁶A in *S. mutans*²⁰. We therefore obtained the *S. mutans* UA159 *ΔtsaC* and *ΔtsaB* strains (kind gift from Robert Quivey, University of Rochester)²⁴, and analyzed t⁶A levels using PHAt6A with the probe targeting tRNA^{lle}_{GAU}. As shown in Figure 4C, strong annealing of the ASL probe was observed in the tRNA extracted from the *ΔtsaC* and *ΔtsaB* strains but also from the *ΔtsaE* mutant. This ambiguity in the PHAt6A necessitated MS analysis (Figure 4B) of the tRNA samples. Indeed *ΔtsaC* and *ΔtsaB* are devoid of t⁶A while *ΔtsaE* maintains trace amounts of t⁶A modified tRNA. With only ~7% of the WT t⁶A levels present in the *ΔtsaE* strain, we are at the limit of the detection of the PHAt6A modification and under the limit of regular HPLC²⁰. Among the platforms for t⁶A detection, only MS offers the sensitivity to detect such low levels of the modification.

We extended the method to other *S. mutans* tRNAs and found that tRNA^{iniMet}_{CAU}, a tRNA known to not be t⁶A modified in bacteria³⁵, showed reduced annealing in the *ΔtsaE* strain compared to WT. This suggests *tsaE* might play a role in tRNA discrimination in the t⁶A insertion machinery. It is possible that tRNA^{iniMet}_{CAU} is targeted for t⁶A modification by mistake when *tsaE* is absent. Further analysis is required to fully elucidate this observation.

Analysis of *tsaBCDE* expression levels and t⁶A content in *S. mutans* in different growth conditions

At the time of the analysis (March 2017 release), 22 transcriptomics experiments for the *S. mutans* U159 strain had been integrated in the PATRIC³⁶ and 25 in the Microbesonline databases³⁷. Using the transcriptomics heatmap analysis tools of pathway databases, we surveyed expression profiles of *prrC* (SMU.893) and of the four t⁶A synthesis genes (*tsaC*/SMU.1083c; *tsaB*/SMU.385; *tsaD*/SMU.387; *tsaE*/SMU.409) and found a few conditions where these genes were differentially-expressed, such as biofilm vs. planktonic growth or when co-cultured with other oral bacteria (Table S2).

As mentioned above, the available transcriptomic data did suggest that the genes encoding for the t⁶A synthesis proteins might be differentially expressed in biofilm vs planktonic growth. To explore this further, cells were grown in rich (BHI) media and in semi-defined media containing sucrose (which promotes biofilm growth)³⁸. Cells were harvested from these two culture conditions at 4 different growth phases: early exponential (4 h growth), mid

exponential (6 h growth), late exponential (8 h growth), and stationary phase (12 h growth) (Figure S2). tRNA was extracted from cells harvested from each growth phase and growth condition, and analyzed via PHAt6A and by LC-MS/MS. The PHAt6A shows an increase in signal in the ASL from early exponential (4 h) to stationary phase (12 h) (Figure 5), suggesting that t⁶A levels decrease in a growth-phase dependent manner. The samples were analyzed via MS on two separate occasions and both analysis showed a similar trend of decreasing t⁶A levels along the growth curve for both BHI and biofilm media. However, there is no statistically significant difference in the degree of t⁶A modification for each of these time points (Figure S3). This seeming disparity in results between the two methods arises from the scope of each analysis. MS quantifies t⁶A modification from all tRNA isoacceptors where subtle variations in t⁶A levels of a few tRNA species may be undetectable. In contrast, PHAt6A reports only on a specific tRNA species allowing for isoacceptor-specific monitoring of t⁶A levels. Expression of *prcC* and of the t⁶A biosynthesis genes were also measured by quantitative real-time PCR (qPCR) in the same set of biological samples. Expression of the t⁶A synthesis genes correlated well with the PHAt6A results, whereby expression of most t⁶A biosynthesis genes and of *prcC* decreased during stationary phase in both BHI and biofilm media (Figure 6A). The only exception to this pattern was in *tsaD* expression, which increased in stationary phase relative to exponential growth phase. The same pattern of growth phase dependent gene expression was observed in both BHI and biofilm media cultures (Figure 6A). Moreover, when directly comparing expression of each gene between growth conditions at each time point (Figure 6B), stationary phase *tsaC* expression was increased 2.5-fold in biofilm media relative to BHI.

Discussion

Recent studies in different model organisms have shown that levels of tRNA modification levels can be fine-tuned to specifically regulate the translation efficiency of specific genes^{39,40}. To date, no such regulation has been observed with t⁶A dependent codons, and it is not known whether t⁶A levels are regulated in any model system. Indeed, the identity of the complete set of genes involved in t⁶A synthesis were only discovered within the last five years⁴¹. In addition, the methods available for t⁶A detection did not allow, until very recently, any physiological studies that could address potential regulation mechanisms. Advances in MS analytical methods, as well as the hybridization based

PHAt6A assay, described in this present paper, have now solved this issue. Using these tRNA modification profiling platforms, the ratios of specific modifications found in bulk tRNA extracted from different conditions can be captured. Recent studies have shown that levels of t⁶A and ms²t⁶A vary accordingly to fluctuations in tRNA modification profiles in *Mycobacterium tuberculosis* under hypoxic conditions⁴⁰, and yeast under different stress conditions⁴³. The MS platform is quantitative for the total amount of t⁶A but is unable to discriminate between the different tRNAs. To identify the specific tRNA modifications in a sequence context, another MS-based platform called the RNA modification mapping approach can be used. This method involves base-specific RNase digestion to the oligonucleotide level. These RNase digestion products are separated and analyzed by LC-MS/MS from which the identity and site of modification can be determined⁴⁴. Whereas MS-based platforms are accurate and robust, the cost of, and access to, such detection platforms is a major challenge. Herein lies the advantage of the PHAt6A assay, a cost-effective and universally accessible method for t⁶A detection. This method allows detection of t⁶A levels in specific tRNAs in very low sample quantities (only 10 ng of bulk tRNA are required) therefore facilitating analysis of samples from limited biological sources. Moreover, PHAt6A enables one to survey t⁶A levels in many replicates over multiple growth conditions. In fact, this assay has already been used to monitor t⁶A variations in *TCS3* mutants in *Drosophila melanogaster*³⁴. With the recent discovery that mutations in the Human Tcs4 (Kae1) gene lead to severe disease⁴⁵, methods to easily detect t⁶A levels in human cells could have diagnostic value.

The PHAt6A assay was used to analyze t⁶A levels in different tRNAs extracted from *S. mutans* WT, $\Delta tsaE$, $\Delta tsaC$ and $\Delta tsaD$ strains and showed that: 1) t⁶A is dispensable in *S. mutans*; 2) *tsaC* and *tsaB* are strictly required for t⁶A synthesis; 3) the absence of *tsaE* significantly reduces the amounts of t⁶A, and TsaE is not strictly required for t⁶A synthesis, instead possibly playing a role in specificity (targeting the correct tRNA) or in regulation of t⁶A levels.

The first study on regulation of t⁶A synthesis genes was recently published in the *Mycobacterium tuberculosis* model⁴⁶. The *tsaD*, *tsaB* and *tsaE* genes are in the same operon with quite a complex regulation. Specific expression of *tsaD* was observed under a few conditions such as H₂O₂ exposure⁴⁶. The *S. mutans tsaE* (*brpB*) gene is co-transcribed with the regulator gene *brpA*²² (Figure S4), which plays a role in resistance to various antibiotic and environmental stressors^{22,23}. The *S. mutans tsaB* and *tsaD* genes are in a predicted operon that encodes a MarR-type regulator

(SMU.384) of unknown function³⁷ (Figure S4). Results from available transcriptomic data (Table S2) and the qPCR results presented here (Figure 6 and Supplemental data 1), do suggest that the expression of *S. mutans* t⁶A genes is growth-phase dependent, but further experiments will be required to fully understand the nature of this regulation.

The PrrC ACNases from *E. coli* or *S. mutans* were only toxic in yeast strains harboring t⁶A. Combined with the prior results that showed that PrrC was toxic to strains missing the mcm⁵U₃₄ modification⁴⁷, it is clear t⁶A is a positive determinant for PrrC. Attempts to purify recombinant WT PrrC for structure/function studies are confounded by the inhibition of protein synthesis elicited when PrrC begins to accumulate. The *tcs8Δ* yeast strain is resistant to PrrC but grows better than the other t⁶A deficient yeast strains and could be used as a host for the large-scale expression of the toxin.

The presence of PrrC in *S. mutans*, an organism where t⁶A is dispensable, raises questions and avenues for future work. Recent single cell analysis experiments have shown that subpopulations of *S. mutans* cells in biofilm have different fates: growth, dormancy or death depending on the expression of specific toxins⁴⁸. Given that both *prrC* and *tsaE* expression are down-regulated in a *brpA* mutant (Table S2) and BrpA is thought to respond to cell envelope stress²², could downregulation of t⁶A levels protect a subpopulation from stress-induced PrrC? Further studies are required to explore the physiological role of PrrC in *S. mutans* and involvement of t⁶A in mechanisms of toxin resistance.

Methods

Strains and Growth Conditions

A list of all organisms used in this study can be found in Table S3. Yeast strains were grown on YPD (DIFCO Laboratories) at 30°C. Synthetic minimal media, with or without agar, with or without dropout supplements (-uracil, -ura; -leucine, -leu; -histidine, -his) were purchased from Clontech (Palo Alto, CA) and prepared as recommended by the manufacturer. Glucose (Glu, 2% w/v), Glycerol (Gly, 4% w/v), 5-fluoro-orotic acid (5-FOA, 0.1% w/v) and G418 (300 µg/mL) were used when appropriate. Yeast transformations were carried out using frozen competent cells as

described⁴⁹ with plating onto the appropriate media. *E. coli* strains were grown in LB (1% tryptone w/v, 0.5% yeast extract w/v, and 1% salt w/v; 1.5% agar w/v was added for plates) at 37 °C, unless otherwise stated. When necessary, LB was supplemented with kanamycin (Kn, 50 µg/mL), ampicillin (Ap, 100 µg/mL), or chloramphenicol (Cm, 35 µg/mL). *S. mutans* was grown in Brain Heart Infusion media at 37°C in a CO₂ incubator. When necessary, 5 µg/µL of erythromycin, kanamycin (50 µg/mL), and spectinomycin was added. For phenotype screens, yeast cultures were grown in the media listed in the figure to saturation, washed, normalized to an OD₆₀₀ of 1.0 and 5 µL of 1:10 serial dilutions were spotted on the listed media with the supplements listed in the figure and text. Galactose (2% w/v) and Raffinose (1% w/v) was added when needed.

Bioinformatics

Transcriptomics data was taken from the PATRIC database where as of March 2017, 22 experiments for *S. mutans* were available³⁶. Microbesonline was also used as a resource for microarray data and operon prediction for *S. mutans*³⁷. Resources at the National Center for Biotechnology Information (NCBI) and BLAST tools were used⁵⁰. tRNA gene sequences were taken from the GtRNadb: Genomic tRNA Database⁵¹.

Extraction of bulk tRNAs and Preparation of *in vitro* transcribed tRNA

Bulk tRNA were prepared as previously described using acid buffered-phenol (phenol saturated with 50 mM sodium acetate, pH 5.8) and alcohol precipitation⁵². The template for producing *E. coli* tRNA^{Ile}_{GAU} transcript was produced via a Klenow extension reaction⁵³ with the oligonucleotides 5'-AATTCCTGCAGTAATACGACTCACTATAAGGCTTGTAGCTCAGGT GGTTAGAGCGC-3' and 5'-TGGTAGGCCTGAGTGGACTTGAACCACCGACCTCACCTT ATCAGGGGTGCGCTCTAAC-3'. The template for *E. coli* tRNA^{Thr}_{GGU} utilized the plasmid pCDI147 which had been linearized by *MvaI* to allow for run-off transcription. pCDI147 was generated using two ligation events. First, the ligation of 6 oligonucleotides 5'-AGCTTTAATA CGACTCACTATAGGGGCTGATATGGCTCAG-3', 5'-TTGGTAGAGCGCACCTTGGTAG GGGTGGGGTCCCCAGTTCGACTCTGGG-3', 5'-TATCAGCACCATATGCTAGTTATTGC TCAGG-3', 5'-GATCCCTGAGCAATAACTAGC-3', 5'-

ATATGGTGCTGATACCCAGAGTC GACTGGGGACCCACCCCTACCAAGGG-3', and 5'-TGCCTCTACCAACTGAGCCATAT CAGCCCCTATAGTGAGTCGTATTAA-3'. This oligonucleotide was subsequently digested with *Bam*HI/*Hind*III before a second ligation into a similarly treated pUC18 plasmid to generate pCDI147. Transcription reactions were run for four hours at 37 °C in 80 mM HEPES (pH 7.4), 2.0 mM spermidine, 24 mM MgCl₂, 2.0 mM ribonucleotide triphosphates (NTPs), 3 μM template, and 2.5 μg/mL of T7 polymerase. The RNA products generated in the transcription reactions were precipitated by the addition of 0.1 volume 8.0 M ammonium acetate, 3 volumes of 100% ethanol, and cooling at -80 °C for 30 minutes, then pelleted by centrifugation at 15,000 RCF for 30 minutes at 4 °C, and resuspended in 50 mM HEPES (pH 7.4), 2.0 mM EDTA. The solutions were mixed 1:1 with formamide, heated at 90 °C for 5 minutes, and snap cooled on ice before being purified via Urea-PAGE electrophoresis (10%). The RNA was extracted by cutting the excised band from the Urea-PAGE gel, slicing it into 1 cm cubes, followed by adding 10 mL HEPES (pH 7.4) 2 mM EDTA per 1 g of gel. This suspension was then placed at 4 °C with agitation overnight. The soluble portion of the suspension was then precipitated as previously described and resuspended in water. The tRNA solution was then frozen at -80 °C before lyophilization.

Positive Hybridization in the Absence of t6A Assay

Blotting. tRNAs were diluted to the appropriate concentration (3 μg – 1ng/μL) to which 3 volumes of denaturing solution (500 μL formamide, 162 μL 37% formaldehyde, 100 μL RNase-free 10X MOPS) was added. tRNAs were denatured at 85°C for 15 min and cooled to 4°C for 2 min and the final volume was adjusted to 30 μL with 10X SSC (1.5 M sodium chloride, 0.15 M sodium citrate). Biotinylated A membrane (Thermo Scientific) was rehydrated in 10X SSC for at least 10 min and placed in a dot blot vacuum manifold (Bio-Rad). Each of the wells were rinsed twice with 0.5 mL 10X SSC before applying the denatured tRNA samples. The wells were rinsed twice with 10X SSC before removing the membrane from the apparatus. The membrane was dried at in an 80°C incubator for 30 seconds followed by RNA crosslinking at 120 mJ/cm² (optimal crosslink mode in Fisher Biotech UV Crosslinker FB-UV XL-1000).

Hybridization. The membrane was rehydrated in 10X SSC for 1 minute and pre-hybridized for 30–60 min at 42°C with pre-warmed Dig Easy Hyb (Roche). One μL of 100 μM biotinylated probes (Listed in Table S1) per 5 cm² membrane

was added to 80 μ L DIG Easy Hyb and heat denatured at 95°C for 10 minutes followed by cooling to 4°C for 2 min. The denatured probes were applied to the pre-hybridized membrane and incubated at 39°C for at least 16 hours with moderate rocking.

Washing. Hybridization solution was poured off and two types of washes was implemented: The low stringency wash consists of 3 washes with wash buffer (2x SSC/0.2% SDS) for 10 min while the high stringency wash adds 1 additional wash at room temp for 10 min and 1 final wash at 55°C for 15 min. For *S. cerevisiae* tRNA^{lle} GAU, membrane probed with T Ψ C was subjected to low stringency washing while the membrane probed with ASL required the high stringency wash to reduce background. For *E. coli* and *S. mutans* tRNAs, low stringency washing for both membranes were sufficient. Visualization was performed as described by the manufacturer of North2South Chemiluminescent Detection Kit (Thermo Scientific No. 17097)

Quantitative Real-time PCR (qPCR)

All *S. mutans* UA159 cultures were grown at 37 °C, 0 RPM in a 5% CO₂ incubator. For each experiment, *S. mutans* was freshly streaked from a 40% (vol vol⁻¹) glycerol stock (stored at -80°C) onto Brain heart infusion (BHI) agar and grown for 48 h. A single colony was then inoculated into 40 ml BHI broth, and grown for 18 hours. For each growth experiment (n = 3), the *S. mutans* 18 hour culture was diluted to an optical density at 600 nm (OD₆₀₀) = 0.05, in a 0.4 media/flask volume ratio, and grown in BHI or Biofilm Media containing 11 mM glucose and 10 mM sucrose³⁸. Culture samples were collected from each flask at 4, 6, and 12 hours growth (corresponding to early exponential, late exponential, and stationary phase), harvested by centrifugation, and cell pellets were stored at -80 °C in RNeasy Lysis Buffer (Thermo Fisher Scientific). RNA was subsequently isolated with the RNeasy Kit (Qiagen) and FASTPREP lysing matrix B tubes (MP Biomedical) using previously-described methods^{54,55}. Each RNA sample was then subjected to a second DNase treatment using the TURBO DNA-free™ Kit (Thermo Fisher Scientific) per the manufacturer's protocols. Lack of contaminating genomic DNA in each RNA sample was determined using PCR and *S. mutans gyrB* primers. RNA samples (0.750 μ g) were subsequently converted to cDNA using the iScript Reverse Transcriptase kit (BioRad). Expression of genes of interest was measured in the cDNA from each sample by

quantitative real-time qPCR using iQ SYBR green supermix (BioRad) and the CFX Connect System (BioRad) following previously-published qRT-PCR protocols⁵⁶. The Livak method ($2^{-\Delta\Delta Ct}$)⁵⁷ was used to calculate the relative fold change between the calibrator samples (indicated in each figure legend) and test samples. Primers specific to the housekeeping gene *gyrB* (*gyrB-F/gyrB-R*) were used as the reference gene (Table S4).

Mass Spectrometry

Total tRNA samples were digested with purified RNase T1 (50 U/ μ g tRNA) in a 220 mM ammonium acetate buffer for 2 h at 37°C. Samples were vacuum dried and resuspended with 10 μ L mobile phase A for LC-MS/MS analysis. The RNase digestion products were separated on a Poroshell 120 EC-C18 column (1 \times 50 mm and 2.7 μ m pore size, column oven at 30 °C) using a Thermo Surveyor HPLC attached to a Thermo LTQ-XL (Thermo Scientific, Waltman, MA) linear ion trap mass spectrometer. Mobile phase A (MPA) consists of 8 mM TEA/200 mM HFIP, pH 7 and mobile phase B is 50% MPA and methanol with a flow rate set at 50 μ L/min. The LC gradient initiated at 10%B then increased linearly to 60%B for 32 min, followed by 95%B for 5 min before a minimum 20 min re-equilibration period at 10%B. The source was set at the following conditions: capillary temperature was set at 275 °C, spray voltage of 4 kV and 35, 14 and 10 arbitrary flow units of sheath, auxiliary and sweep gas, respectively. The mass spectra were recorded in negative polarity. The entire run was divided into two segments, each with five scan events. The product ion's sequence information was obtained by collision induced dissociation (CID) in scan events 2--5. Data acquisition was through Thermo Xcalibur software.

Analysis of t⁶A modifications in *S. mutans* grown in rich media and biofilm media

Bulk tRNA (1 μ g) from each sample was hydrolyzed to ribonucleosides in a reaction containing Benzonase (0.375 U), calf intestine alkaline phosphatase (8.5 U), phosphodiesterase I (0.05 U), cofomycin (3.5 μ M; nucleobase deaminase inhibitor), deferoxamine (3 mM; antioxidant), butylated hydroxytoluene (0.3 mM; antioxidant) HEPES (500 mM, pH 8) and MgCl₂ (5 mM) in a final reaction volume of 50 μ L. The reaction was allowed to proceed for 2 h at 37 °C and was stopped by removal of the enzymes by microfiltration with 10,000 Da spin filters. Following the addition of [¹⁵N₅]-2'-deoxyadenosine as an internal standard for data normalization, ribonucleosides were resolved on a Synergy Fusion RP

HPLC column (2.5 μm particle size, 100 \AA pore size, 100 mm length, 2 mm inner diameter; Phenomenex, Torrance, CA, USA) mounted on an Agilent 1290 series HPLC system equipped with a diode array detector (DAD). The ribonucleosides were eluted at a flow rate of 0.35 ml/min and a column temperature of 35 $^{\circ}\text{C}$ with a gradient consisting of 5 mM ammonium acetate (A) and acetonitrile (B) as follows: 0–1 min 100% A, 1–10 min 0–10% B, 10–24 min 10–40% B, 24–44 min 40–80% B, and 44–49 min 100% A to regenerate the column. The column, with its eluent directed through the DAD to record the 260 nm absorbance of canonical ribonucleosides, was coupled to an Agilent 6430 triple quadrupole mass spectrometer operated in positive ion mode with the following parameters: electrospray ionization (ESI-MS), fragmentor voltage (average) 80 V, cell accelerator voltage 2 V, N_2 -gas temperature 350 $^{\circ}\text{C}$, N_2 -gas flow 10 l/min, nebulizer 40 p.s.i., capillary 3500 V. Using dynamic multiple reaction monitoring (MRM), modified ribonucleosides were identified based on retention time ($t^6\text{A}$ at 7.9–8.3 min) and mass transition (m/z 413 \rightarrow 281 for loss of ribose from $t^6\text{A}$). The signal for $t^6\text{A}$ was normalized by dividing by the peak area of the [$^{15}\text{N}_5$]-dA standard (inter-sample variation) and by the summed MRM peak areas of the canonical ribonucleosides (input RNA variation). The normalized peak areas of three biological replicates were then averaged.

Acknowledgments

We would like to thank Robert Quivey (University of Rochester) for the *S. mutans* ΔtsaC and ΔtsaB strains, and Tom Wen (Louisiana State University Health Sciences Center) for the *S. mutans* ΔbrpB strain. We would also like to thank Lin Zheng and Robert Burne (University of Florida) for sharing their transcriptomics results on *S. mutans*.

Funding

This work was supported by the National Institutes of Health (NIH) under grant R01 GM70641 to Valérie de Crécy-Lagard, partially under grant AI118999 to Kelly C. Rice, and the Florida Education Fund McKnight Doctoral Fellowship awarded to Silvia S. Orsini.

References

1. El Yacoubi B, Bailly M, de Crécy-Lagard V. Biosynthesis and function of posttranscriptional modifications of transfer RNAs. *Ann Rev Gen* 2012; 46:69–95.
2. Kaufmann G. Anticodon nucleases. In: *Trends in Biochemical Sciences*. 2000. page 70–74.
3. Cruz JW, Woychik NA. tRNAs taking charge. In: *Pathogens and Disease* 74. 2016.
4. Ogawa T, Tomita K, Ueda T, Watanabe K, Uozumi T, Masaki H. A cytotoxic ribonuclease targeting specific transfer RNA anticodons. *Science* 1999; 283:2097–2100.
5. Tomita K, Ogawa T, Uozumi T, Watanabe K, Masaki H. A cytotoxic ribonuclease which specifically cleaves four isoaccepting arginine tRNAs at their anticodon loops. *Proc Natl Acad Sci* 2000; 97:8278–8283.
6. Cruz JW, Sharp JD, Hoffer ED, Maehigashi T, Vvedenskaya IO, Konkimalla A, Husson RN, Nickels BE, Dunham CM, Woychik NA. Growth-regulating *Mycobacterium tuberculosis* VapC-mt4 toxin is an isoacceptor-specific tRNase. *Nat Commun* 2015; 6:7480.
7. Winther KS, Gerdes K. Enteric virulence associated protein VapC inhibits translation by cleavage of initiator tRNA. In: *Proceedings of the National Academy of Sciences* 108. 2011. page 7403–7407.
8. Schifano JM, Cruz JW, Vvedenskaya IO, Edifor R, Ouyang M, Husson RN, Nickels BE, Woychik NA. tRNA is a new target for cleavage by a MazF toxin. *Nucleic Acids Res* 2016;:1256–1270.
9. Klassen R, Paluszynski JP, Wemhoff S, Pfeiffer A, Fricke J, Meinhardt F. The primary target of the killer toxin from *Pichia acaciae* is tRNA^{Gln}. *Mol Microbiol* 2008; 69:681–697.
10. Lu J, Huang B, Esberg A, Johansson MJO, Byström AS. The *Kluyveromyces lactis* gamma-toxin targets tRNA anticodons. *RNA* 2005; 11:1648–54.

11. Levitz R, Chapman D, Amitsur M, Green R, Snyder L, Kaufmann G. The optional *E. coli prr* locus encodes a latent form of phage T4-induced anticodon nuclease. *EMBO J* 1990; 9:1383–9.
12. Rabussay D, Geiduschek EP. Phage T4-modified RNA polymerase transcribes T4 late genes in vitro. *Proc Natl Acad Sci U S A* 1977; 74:5305–9.
13. Kaufmann G, David M, Borasio GD, Teichmann A, Paz A, Amitsur M. Phage and host genetic determinants of the specific anticodon loop cleavages in bacteriophage T4-infected *Escherichia coli* CTr5X. *J Mol Biol* 1986; 188:15–22.
14. Jiang Y, Meidler R, Amitsur M, Kaufmann G. Specific interaction between anticodon nuclease and the tRNA^{Lys} wobble base. *J Mol Biol* 2001; 305:377–88.
15. Meidler R, Morad I, Amitsur M, Inokuchi H, Kaufmann G. Detection of anticodon nuclease residues involved in tRNA^{Lys} cleavage specificity. *J Mol Biol* 1999; 287:499–510.
16. Meineke B, Schwer B, Schaffrath R, Shuman S. Determinants of eukaryal cell killing by the bacterial ribotoxin PrrC. *Nucleic Acids Res* 2011; 39:687–700.
17. Machnicka MA, Milanowska K, Oglou OO, Purta E, Kurkowska M, Olchowik A, Januszewski W, Kalinowski S, Dunin-Horkawicz S, Rother KM, et al. MODOMICS: a database of RNA modification pathways–2013 update. *Nucleic Acids Res* 2013; 41:262–267.
18. Sarin LP, Leidel SA. Modify or die?--RNA modification defects in metazoans. *RNA Biol* 2014; 11:1555–67.
19. Thiaville PC, Iwata-Reuyl D, de Crécy-Lagard V. Diversity of the biosynthesis pathway for threonylcarbamoyladenine (t⁶A), a universal modification of tRNA. *RNA Biol* 2014; 11:1529–1539.
20. Thiaville PC, Yacoubi BE, Kohrer C, Thiaville JJ, Deutsch C, Iwata-Reuyl D, Bacusmo JM, Armengaud J, Bessho Y, Wetzel C, et al. Essentiality of threonylcarbamoyladenine (t⁶A), a universal tRNA modification in bacteria. *Mol Microbiol* 2015; 98:1199–1221.

21. Bitoun JP, Liao S, Xie GG, Beatty WL, Wen ZT. Deficiency of BrpB causes major defects in cell division, stress responses and biofilm formation by *Streptococcus mutans*. *Microbiology* 2014; 160:67–78.
22. Bitoun JP, Liao S, Yao X, Ahn S-J, Isoda R, Nguyen AH, Brady LJ, Burne RA, Abranches J, Wen ZT. BrpA Is Involved in Regulation of Cell Envelope Stress Responses in *Streptococcus mutans*. *Appl Environ Microbiol* 2012; 78:2914–22.
23. Wen ZT, Burne RA. Functional genomics approach to identifying genes required for biofilm development by *Streptococcus mutans*. *Appl Environ Microbiol* 2002; 68:1196–203.
24. Quivey RG, Grayhack EJ, Faustoferri RC, Hubbard CJ, Baldeck JD, Wolf AS, MacGilvray ME, Rosalen PL, Scott-Anne K, Santiago B, et al. Functional profiling in *Streptococcus mutans*: construction and examination of a genomic collection of gene deletion mutants. *Mol Oral Microbiol* 2015; 30:474–95.
25. Lemos JA, T. A. Brown JA Jr, Burne RA. Characteristics of *Streptococcus mutans* strains lacking the MazEF and RelBE toxin-antitoxin modules. *FEMS Microbiol Lett* 2005; 253:251–257.
26. Syed MA, Koyanagi S, Sharma E, Jobin MC, Yakunin AF, Levesque CM. The chromosomal *mazEF* locus of *Streptococcus mutans* encodes a functional type II toxin-antitoxin addiction system. *J Bacteriol* 2011; 193:1122–1130.
27. Meineke B, Shuman S. Determinants of the cytotoxicity of PrrC anticodon nuclease and its amelioration by tRNA repair. *RNA* 2012; 18:145–54.
28. Uzan M, Miller ES. Post-transcriptional control by bacteriophage T4: mRNA decay and inhibition of translation initiation. *Virology* 2010; 7:360.
29. Leung V, Dufour D, Celine M. Lévesque. Death and Survival in *Streptococcus mutans*: Differing Outcomes of a Quorum-Sensing Signalling Peptide. In: *Frontiers in Microbiology* 6. 2015.

30. Lamichhane TN, Blewett NH, Crawford AK, Cherkasova VA, Iben JR, Begley TJ, Farabaugh PJ, Maraia RJ. Lack of tRNA modification isopentenyl-A37 alters mRNA decoding and causes metabolic deficiencies in fission yeast. *Mol Cell Biol* 2013; 33:2918–29.
31. Lamichhane TN, Mattijssen S, Maraia RJ. Human Cells Have a Limited Set of tRNA Anticodon Loop Substrates of the tRNA Isopentenyltransferase TRIT1 Tumor Suppressor. *Mol Cell Biol* 2013; 33:4900–8.
32. Yarham JW, Lamichhane TN, Pyle A, Mattijssen S, Baruffini E, Bruni F, Donnini C, Vassilev A, He L, Blakely EL, et al. Defective i⁶A37 modification of mitochondrial and cytosolic tRNAs results from pathogenic mutations in TRIT1 and its substrate tRNA. *PLoS Genet* 2014; 10:e1004424.
33. Thiaville PC, Legendre R, Rojas-Benítez D, Baudin-Baillieu A, Hatin I, Chalancon G, Glavic A, Namy O, de Crécy-Lagard V. Global translational impacts of the loss of the tRNA modification t⁶A in yeast. *Microb Cell* 3:29–45.
34. Rojas-Benitez D, Thiaville PC, de Crécy-Lagard V, Glavic A. The Levels of a Universally Conserved tRNA Modification Regulate Cell Growth. *J Biol Chem* 2015; 290:18699–707.
35. Jühling F, Mörl M, Hartmann RK, Sprinzl M, Stadler PF, Pütz J. tRNADB 2009: compilation of tRNA sequences and tRNA genes. *Nucleic Acids Res* 2009; 37:D159–62.
36. Wattam AR, Davis JJ, Assaf R, Boisvert S, Brettin T, Bun C, Conrad N, Dietrich EM, Disz T, Gabbard JL, et al. Improvements to PATRIC, the all-bacterial Bioinformatics Database and Analysis Resource Center. *Nucleic Acids Res* 2017; 45:D535–42.
37. Dehal PS, Joachimiak MP, Price MN, Bates JT, Baumohl JK, Chivian D, Friedland GD, Huang KH, Keller K, Novichkov PS, et al. MicrobesOnline: an integrated portal for comparative and functional genomics. *Nucleic Acids Res* 2010; 38:D396–400.
38. Biswas I, Drake L, Biswas S. Regulation of *gbc* Expression in *Streptococcus mutans*. *J Bacteriol* 2007; 189:6521–31.

39. Duechler M, Leszczyńska G, Sochacka E, Nawrot B. Nucleoside modifications in the regulation of gene expression: focus on tRNA. *Cell Mol Life Sci* 2016; 73:3075–95.
40. Chionh YH, McBee M, Babu IR, Hia F, Lin W, Zhao W, Cao J, Dziergowska A, Malkiewicz A, Begley TJ, et al. tRNA-mediated codon-biased translation in mycobacterial hypoxic persistence. *Nat Commun* 2016; 7.
41. Deutsch C, El Yacoubi B, de Crécy-Lagard V, Iwata-Reuyl D. Biosynthesis of threonylcarbamoyl adenosine (t⁶A), a universal tRNA nucleoside. *J Biol Chem* 2012; 287:13666–73.
42. Lin C-J, Smibert P, Zhao X, Hu JF, Ramroop J, Kellner SM, Benton MA, Govind S, Dedon PC, Sternglanz R, et al. An extensive allelic series of *Drosophila kael1* mutants reveals diverse and tissue-specific requirements for t⁶A biogenesis. *RNA N Y N* 2015; 21:2103–18.
43. Cai WM, Chionh YH, Hia F, Gu C, Kellner S, McBee ME, Ng CS, Pang YLJ, Prestwich EG, Lim KS, et al. A platform for discovery and quantification of modified ribonucleosides in RNA: Application to stress-induced reprogramming of tRNA modifications. *Methods Enzymol* 2015; 560:29–71.
44. Ross R, Cao X, Yu N, Limbach PA. Sequence mapping of transfer RNA chemical modifications by liquid chromatography tandem mass spectrometry. *Methods San Diego Calif* 2016; 107:73–8.
45. Edvardson S, Prunetti L, Arraf A, Haas D, Bacusmo JM, Hu JF, Ta-Shma A, Dedon PC, de Crécy-Lagard V, Elpeleg O. tRNA N⁶-adenosine threonylcarbamoyltransferase defect due to KAE1/TCS3 (OSGEP) mutation manifest by neurodegeneration and renal tubulopathy. *Eur J Hum Genet EJHG* 2017; 25:545–51.
46. Bhat AH, Pathak D, Rao A. The *alr-groEL1* operon in *Mycobacterium tuberculosis*: an interplay of multiple regulatory elements. *Sci Rep* 2017; 7:43772.
47. Meineke B, Schwer B, Schaffrath R, Shuman S. Determinants of eukaryal cell killing by the bacterial ribotoxin PrrC. *Nucleic Acids Res* 2011; 39:687–700.
48. Shields RC, Burne RA. Growth of *Streptococcus mutans* in Biofilms Alters Peptide Signaling at the Sub-population Level. *Front Microbiol* 2016; 7.

49. Gietz RD, Schiestl RH. Frozen competent yeast cells that can be transformed with high efficiency using the LiAc/SS carrier DNA/PEG method. *Nat Protoc* 2007; 2:1–4.
50. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. *J Mol Biol* 1990; 215:403–10.
51. Chan PP, Lowe TM. GtRNAdb 2.0: an expanded database of transfer RNA genes identified in complete and draft genomes. *Nucleic Acids Res* 2016; 44:D184–9.
52. El Yacoubi B, Lyons B, Cruz Y, Reddy R, Nordin B, Agnelli F, Williamson JR, Schimmel P, Swairjo MA, de Crécy-Lagard V. The universal YrdC/Sua5 family is required for the formation of threonylcarbamoyladenosine in tRNA. *Nucleic Acids Res* 2009; 37:2894–909.
53. Sherlin LD, Bullock TL, Nissan TA, Perona JJ, Lariviere FJ, Uhlenbeck OC, Scaringe SA. Chemical and enzymatic synthesis of tRNAs for high-throughput crystallization. *RNA* 2001; 7:1671–8.
54. Ahn S-J, Qu M-D, Roberts E, Burne RA, Rice KC. Identification of the *Streptococcus mutans* LytST two-component regulon reveals its contribution to oxidative stress tolerance. *BMC Microbiol* 2012; 12:187.
55. Patton TG, Rice KC, Foster MK, Bayles KW. The *Staphylococcus aureus* *cidC* gene encodes a pyruvate oxidase that affects acetate metabolism and cell death in stationary phase. *Mol Microbiol* 2005; 56:1664–74.
56. Lewis AM, Rice KC. Quantitative Real-Time PCR (qPCR) Workflow for Analyzing *Staphylococcus aureus* Gene Expression. *Methods Mol Biol Clifton NJ* 2016; 1373:143–54.
57. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods San Diego Calif* 2001; 25:402–8.




Figure 1. Mapping of nucleoside modifications and targets for oligo probes on tRNA. Modifications on positions 34 and 37 are listed in their respective boxes. Target for ASL probe is depicted in green and target for the TΨC probe is depicted in red.




Figure 2. Resistance of t^6A deficient yeast strains to PrrC toxins. A. Cytosolic *tcs3Δ* is resistant to PrrC_{Ec} while mitochondrial *tcs4Δ* is not. B. *tcs8Δ* is resistant to both PrrC_{Ec} and PrrC_{Sm}, while the PrrC_{Ec} K46A variant has no effect on growth. Cells were grown in synthetic minimal media containing agar and leucine dropout supplement (SD-Leu). Galactose (2% w/v) and raffinose (1% w/v) were added where necessary (SD-Leu Gal/Raf). Strains were incubated at 30°C for ~72 hours.




Figure 3. PHAt6A assay with yeast and *E. coli* bulk tRNAs. A. PHAt6A with tRNA isolated from wild type yeast and t⁶A deficient strains. B. Sensitivity of the PHAt6A method using yeast tRNAs. C. PHAt6A with wild type *E. coli* and *in vitro* transcribed tRNAs.




Figure 4. Detection of t⁶A in *S. mutans* wild-type and mutant strains. A. PHAt6A with *S. mutans* $\Delta tsaE$. B. Mass spec analysis of t⁶A modification in tRNA^{Ile}_{GAU} showing no t⁶A in $\Delta tsaC$ and $\Delta tsaB$ but trace amounts are detected in $\Delta tsaE$. C. PHAt6A with t⁶A deficient strains $\Delta tsaC$, $\Delta tsaB$, $\Delta tsaE$ using oligonucleotides specific to tRNA^{Ile}_{GAU}. D. PHAt6A with wild type UA159 and $\Delta tsaE$ using probes for tRNA^{iniMet}_{CAU}.




Figure 5. Detection of t^6A in *S. mutans* UA159 tRNA grown in Biofilm and Rich Media. PHAt6A of tRNA isolated from the following time points: 4h – Early-exponential, 6h – Mid-exponential, 8h – Late-exponential, and 12h – Stationary phase.




Figure 6. *S. mutans* UA159 gene expression profile for $\Delta tsaC$, $\Delta tsaB$, $\Delta tsaD$, $\Delta tsaE$, and *prcC* genes during growth in Biofilm and Rich media (BHI). A. Fold change difference of each of the genes with respect to 4h time point (calibrator). * indicates statistical significance ($P < 0.05$, Student-Newman-Keuls Test) relative to calibrator sample. B. Fold change difference in gene expression at each time point in Biofilm media with respect to Rich media (calibrator). * indicates statistical significance ($P < 0.05$, Two-tailed T-Test) relative to calibrator sample.